Sponsor Should Decide Number Of Applications – Combo Products Coalition
This article was originally published in The Gray Sheet
Executive Summary
FDA should allow companies developing combination products to determine the number of applications to submit for their products, as long as the sponsor's decision is legal, the Combination Products Coalition says
You may also be interested in...
Concept Papers Seek Industry Input On Combo Product Issues
FDA seeks feedback on two concept papers offering preliminary thoughts on adverse event reporting and on the number of applications needed for a combination product
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.